Obesity Drug Developers Aim To Navigate Regulatory Backroads
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
The major lesson of FDA’s serial rejection of three obesity drugs in a six-month span is that safety is paramount in the weight loss space. That’s agreed. But beyond that, it’s tough to know what to expect, and obesity drug developers face an uncertain regulatory path going forward.